ProtaGene

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, they provide advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms. The company's deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk's unique capabilities in vector safety, integration site analysis, and bioinformatics were added to their portfolio, establishing ProtaGene as the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and collaborates with leading biopharmaceutical and gene therapy companies worldwide.

Founded in 1997 and headquartered in Germany, ProtaGene's most recent funding came from a Private Equity Round investment on 20 November 2023, with Ampersand Capital Partners as the investors. The company continues to assert its position as a pivotal player in the biopharmaceutical and gene and cell therapy industries, offering comprehensive services and innovative solutions for its global clientele.